COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation

Completed · Not applicable

Conditions studied: SARS-CoV2 Infection, COVID-19

In brief

SARS-CoV-2 rapid antigen over the counter clinical performance evaluation

Key facts

Study ID

NCT05584176

Run by

MP Biomedicals, LLC

People needed

332

Starts

2021-12-09

Expected to finish

2022-01-21

Last updated by the study team

2023-06-01

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The study population will include subjects from 2 years old to greater than 65 years old.
• Lay subjects who perform the test on themselves must be able to read, write, speak, and understand English.

You may not qualify if…

• Subjects less than 2 years old will be excluded.
• Participants who regularly use home diagnostic tests, such as glucose meters, or are trained medical or laboratory professionals will be excluded.
• Persons under 14 years of age will be excluded from performing the Rapid SARS-CoV-2 Antigen Test on themselves.
• Persons under 2 years of age will be excluded from participation.
• Persons under 18 years of age will be excluded from performing the Rapid SARS-CoV-2 Antigen Test on another qualified participant.

Where it is running

• Accel Research — DeLand, Florida, United States
• Daniel Sarkis — Gainesville, Florida, United States
• Accel Research Site St. Petersburg — St. Petersburg, Florida, United States
• EDP Biotech Corporation — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.